ArticleDiscover oncology2025
Analysis of clinicopathological and molecular characteristics of EBV-associated gastric cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The evolving role of OMICS in gastrointestinal tumor biology and clinical practice.Molecular cancer · 2026Review
- Correlation of tumor-infiltrating lymphocyte spatial distribution patterns with HER2 expression status and prognostic significance in gastric adenocarcinoma: a retrospective study based on digital pathology.American journal of cancer research · 2026Article
- Case Report: Massive polypoid early Epstein-Barr virus-associated gastric carcinoma in a young immunocompromised host.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to explore the clinicopathological and molecular traits of Epstein-Barr virus-associated gastric cancer (EBV-GC).
methodsA retrospective analysis was performed on the clinicopathological features, immunophenotype, and molecular characteristics of seven EBV-GC cases utilizing next-generation sequencing (NGS) technology.
resultsAmong the seven cases, six were male and one was female, aged from 24 to 76 years (mean age: 56 years). Tumor sizes varied between 10 and 100 mm (mean size: 54.2 mm). The tumors were mainly located in the upper and middle regions of the stomach, predominantly exhibiting an ulcerative appearance. Numerous cases were linked with gastric carcinoma with lymphoid stroma. About half of the cases were identified as diffuse type according to the Lauren classification. All cases were in the early stage, with lymph node metastasis being uncommon. Immunophenotyping demonstrated positive Epstein-Barr virus-encoded RNA, common overexpression of programmed death-ligand one, and presence of tumor-infiltrating lymphocytes. Human epidermal growth factor receptor 2 (HER2) and microsatellite instability were negative. The molecular characteristics frequently included PIK3CA and ARID1A mutations, whereas TP53, HER2, EGFR mutations, and deficient mismatch repair were absent.
conclusionEBV-GC is characterized by distinct clinicopathological and molecular features. Pathological examination, immunophenotyping, and NGS provide significant value for diagnosis and therapeutic direction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.